Subtype
Esophageal and Gastroesophageal Junction Carcinoma
CI-CAN-00002608Explore in graph →
460 active trials11 approved drugs34 evidence items
- NCIt
- C203673
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002608Explore in graph →
Clinical trials
1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (120)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06339619 | Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 32 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07452601 | Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC | recruiting | Phase 2 | 90 | Tang-Du HospitalOTHER | 1 | May 28, 2026 |
| clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT05977998 | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06067438 | Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer | recruiting | Phase 2 | 90 | OHSU Knight Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07205731 | Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma(SAFE ESO) | recruiting | Phase 2 | 95 | University Hospital, Clermont-FerrandOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07595770 | Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma(ANCRE) | recruiting | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07432295 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | recruiting | Phase 2 | 180 | I-Mab Biopharma US LimitedINDUSTRY | 3 | May 14, 2026 | clinicaltrials |
| NCT07007182 | Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer | recruiting | Phase 2 | 54 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07178808 | PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER | recruiting | Phase 2 | 30 | Banner HealthOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07559045 | Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 92 | Second Affiliated Hospital of Zunyi Medical UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06846346 | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma(GRACIE) | recruiting | Phase 2 | 88 | UNICANCEROTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer(DUET-GEJ) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07353684 | Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer | recruiting | Phase 2 | 49 | Beijing Friendship HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07484724 | A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 280 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03161522 | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07519486 | Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC(INS-ESCC-CT) | recruiting | Phase 2 | 118 | Sichuan UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07530094 | Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma(STELLAR01) | recruiting | Phase 2 | 98 | Ning Jiang, M.D./Ph.D.OTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06885814 | Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05745857 | Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas(SLURP) | recruiting | Phase 2 | 25 | University Medical Center GroningenOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05927857 | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . | recruiting | Phase 1 / Phase 2 | 45 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05753306 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors(BetaBart) | recruiting | Phase 1 / Phase 2 | 61 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07481058 | KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer | recruiting | Phase 2 | 60 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07457528 | Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC | recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06461910 | Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 30 | Zekuan XuOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07039162 | Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 45 | Ming-Yu LienOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07435454 | Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 22 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07437898 | Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study | recruiting | Phase 2 | 42 | The Affiliated Hospital of Putian UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07385001 | A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC | recruiting | Phase 1 / Phase 2 | 45 | Tang-Du HospitalOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05978193 | Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma(SCR-ESCC-01) | recruiting | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA) | recruiting | Phase 1 / Phase 2 | 117 | Anwaar SaeedOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07311408 | SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure(SHR-2554) | recruiting | Phase 2 | 40 | Jingdong ZhangOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06161818 | Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction(TNT-OES-2) | recruiting | Phase 2 | 216 | Erasmus Medical CenterOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07289997 | Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) | recruiting | Phase 2 | 39 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07290010 | The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 25 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07266493 | Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 26 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07263386 | A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer(ARTEMIS-GC3) | recruiting | Phase 2 | 460 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06576973 | Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06912074 | Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 134 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07086469 | Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04656041 | Folfox+Irinotecan+Chemort In Esophageal Cancer | recruiting | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT05563766 | A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | recruiting | Phase 2 | 78 | VA Office of Research and DevelopmentFED | 1 | Nov 5, 2025 | clinicaltrials |
| NCT07188103 | Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 37 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06601309 | Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC(ESCC) | recruiting | Phase 2 | 90 | Fujian Medical University Union HospitalOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07102901 | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 351 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2026source: clinicaltrials